secwatch.observer — SEC 8-K summary
======================================

Issuer:     Hoth Therapeutics, Inc. (HOTH)
CIK:        0001711786
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001213900-23-015045
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Hoth Therapeutics receives FDA clearance to proceed with Phase 2a trial of HT-001 for EGFR inhibitor skin toxicities
--------------------------------------------------------------------------------

- FDA completed safety review and permitted IND for HT-001 to treat rash and skin disorders from EGFR inhibitor therapy.
- Phase 2a trial (CLEER) is a randomized, placebo-controlled, parallel dose-ranging study.
- European patent application filed for compositions and methods treating lung inflammation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711786/000121390023015045/0001213900-23-015045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711786/000121390023015045/ea174379-8k_hoththera.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-015045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer